Moderna Inc. (MRNA)
Symbol Info
Listed Symbol MRNA
Name Moderna Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $135,068,000
Latest Fiscal EPS $-4.95
Price Info
21 Day Moving Average $15.4412
21 Day EMA $15.052690
50 Day Moving Average $15.2365
50 Day EMA $15.334660
200 Day EMA $17.078930
200 Day Moving Average 18.026380
52 Week High $29.79
52 Week Low $11.54
52 Week Change $
Alpha 0.003101
Beta 0.7484
Standard Deviation 0.212801
R2 0.021207
Periods 10
Share Information
10 Day Average Volume 1,293,695
20 Day Average Volume 2,008,066
30 Day Average Volume 3,527,566
50 Day Average Volume 2,778,394
Outstanding Shares 330,182,202
Float Shares 307,659,687
Percent Float 93.18%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 269
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 17,163,260
Institute Holdings Percent 55.600000
Institute Sold Previous 3 Months 14,899,556
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 8
Insider Holdings Percent 6.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 22,522,515
Price Change
7 Day Price Change $0.7550001
7 Day Percent Change 5.37%
21 Day Price Change $-1.0899992
21 Day Percent Change -6.86%
30 Day Price Change $-2.9700003
30 Day Percent Change -16.70%
Month To Date Price Change $-1.11
Month To Date Percent -6.97%
90 Day Price Change $0.550000
90 Day Percent Change 3.86%
Quarter To Date $-1.11
Quarter To Date Percent -6.97%
180 Day Price Change $-7.7
180 Day Percent Change -34.21%
200 Day Price Change $-5.78
200 Day Percent Change -28.07%
Year To Date $-0.46
Year To Date Percent -3.01%
Profile
Description Moderna Inc is engaged in creating transformative medicines based on messenger RNA, or mRNA. Its therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. The company's approach is to use mRNA medicines to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.
Details
Issue Type CS
Market Cap $4,889,998,412
Sec Type
Auditor Ernst & Young LLP
Total Shares Outstanding 330,182,202
CEO Stephane Bancel
Employees 760
Last Audit UQ
Classification
CIK 0001682852
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 200 Technology Square
Cambridge, MA 2139
Website http://www.modernatx.com
Facisimile +1 617 583-1998
Telephone +1 617 714-6500
Email
Key Ratios
Profitability
EBIT Margin -485
EBITDA Margin -458
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $64,529,000
Revenue Per Share $0.1954
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $4,219,742,655
Price To Sales 75.779860
Price To Free Cash -12.9
PE High Last 5 Years -
Price To Book 3.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 3.7
Financial Strength
Total Debt To Equity 0.0
Int Coverage -158.3
Current Ratio 6.8
Leverage Ratio 1.2
Quick Ratio 6.7
Long Term Debt To Capital 0.02
Assets
Receivables Turnover 2.7
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -29.65
Return On Equity -37.33
Return On Capital -39.09
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MRNA
Moderna
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.